Human Practices

While talking with different stakeholders during our project, they often asked us: "What are Human Practices?" Initially, we answered that human practices are interviewing experts on certain topics, and getting their feedback. But as time passed, and many times we had answered this question, we realized that this is not what the true meaning of human practices is. We realized that it is not bombarding academics with questions and awaiting their replies, or asking companies if they would be interested in selling our product, or asking clinicians about how they conduct their clinical practice. It is about listening, about carefully reading between the lines, about looking at the bigger picture. We learned that every person has their unique perspective and story to tell, and it is on us to share it. 

Every talk we had was different, with different topics discussed, different opinions, and different questions arising. Each talk was individually assessed, to see how we can implement it into our project, how we can give it a voice, and how we can contribute to bridging the gaps mentioned. Even though every talk was different, most of them agreed on one thing: there is not enough research on PMOS.

I love when you do research on PMOS because honestly, there really isn't enough.
Eleni Dubé Zinatelli

After many talks, we became increasingly aware of how big the gap can be. It shocked us. Diagnostic delay, lack of proper medication and lack of awareness, just to name a few. They can all be addressed by doing more research on PMOS, because currently, there is no known cause for this syndrome, nor a proper way to treat it. We wanted to bridge that gap, at least a little, because 10–13% of women suffer from this condition (World Health Organization, 2026). That is why we dedicated our project to PMOS, to raise awareness about it. There can never be enough awareness.

Our conversations fell into three groups, which we treat as the pillars of our human practices work:

Stakeholders

For a project to move beyond a proof-of-conceptA first test showing that an idea can work, before it is developed into something usable., it has to consider, and be considered by, people outside of the laboratory. A therapeutic can reach a patient only if it can be developed, manufactured, classified, prescribed, afforded and trusted. Each of those steps belongs to a different group of people with its own priorities and reasons to say no to it. Throughout the project, we have tried to reach most of these groups, and treat them as participants in the design by implementing their feedback, rather than treating them as obstacles.

By mapping the path our product would have to travel from a construct in the lab to a therapeutic in the clinic, we have identified five groups of stakeholders. They do not form a list, but rather an interdependent cycle: academics develop, industry produces, regulators establish safety, clinicians prescribe, and patients give their feedback, redirecting the research and development. Each group affects the one after it, and the last one closes the cycle back to the first.

Select a slice to read about it.

Integrated HP

Throughout the development of the project, we consulted researchers and experts across different fields to evaluate our assumptions and shape our decisions. We spoke with specialists in steroid-transforming enzymes, PMOS and hyperandrogenismHigher than normal levels or effects of androgens, the male sex hormones such as testosterone. research, microbiome containment, sustainability practice, clinical practice, and innovation management, just to name a few.

Each conversation is summarized below, together with what we learned and how it shaped the project.

Academia

Anna Benrick

Professor in Endocrinology Department of Physiology, University of Gothenburg

Anna Benrick's research focuses on hyperandrogenism and its link to reproductive diseases in females. She was contacted to help us with understanding more about PMOS, hyperandrogenism and the feasibility of our approach. Dr. Benrick confirmed 5β-reductase-targeted androgen reduction is a valid therapeutic approach, and advised us against an androgen-inducible expression strategy, favoring stable overexpressionMaking the cells produce a lot of the enzyme all the time, rather than only when a signal switches it on. instead.

Helena Berglund

Assistant Head of Teacher Education Joint Faculties of Humanities and Theology, Lund University

Helena Berglund is Assistant Head of Teacher Education at Lund University's Joint Faculties of Humanities and Theology, with a research focus on how teacher professionalism can be strengthened through the right conditions in schools and teacher education. Given her expertise, she has insight into how the Swedish school system works and what makes outreach material well-suited for students. We contacted her early on for feedback and support on our high school outreach package, to understand which approaches could realistically create the highest impact. She confirmed our target age (15–18, pre- and post-specialization), pushed us toward hands-on/practical formats over plain lectures, made us consider school segregation, and confirmed language wouldn't be a barrier, given students' English proficiency.

Eduardo Amo González

Doctoral student in Computational Biology Center for Molecular Protein Science, Lund University

Eduardo Amo González is a doctoral student at Lund University, and was a Dry Lab Leader of last year's iGEM Lund Team. He was contacted for advice on how to approach protein and mutation modeling during the early stages of the project, and on which software programs he would recommend. He suggested using ChimeraXA program for visualizing and analyzing 3D molecular structures., as it is user-friendly and suited for beginners. He also introduced us to iGEM at the very beginning of the project and explained what the competition involves.

Integration:

  • Modeling Software - Based on Eduardo's advice, we decided to use ChimeraX for protein visualization and mutation modeling.

Tsz Yan Clement Chan

Associate Professor in Bioengineering Department of Biomedical Engineering, University of North Texas

Dr. Clement Chan is an expert in genetic circuits which can be used for biocontainment. He was contacted to get insight into the possible biocontainment strategies for our product. Based on his feedback, we decided to focus our experimental work on in vitro proof-of-concept only, but discuss the biocontainment theory thoroughly, postponing its practical implementation to future work. We also had to consider our choice of future probiotic chassisThe host organism that carries the engineered genes. based on where testosterone is actually reabsorbed in the gut.

Eleni Dubé Zinatelli

PhD candidate in Experimental Psychology University of Ottawa

Eleni Dubé Zinatelli's doctoral research focuses on the impact of PMOS on mental health. She was contacted to discuss the mental health burden of PMOS and how specific symptoms could correlate with psychological distress. She noted how reducing hyperandrogenism symptoms such as hirsutismExcess dark, coarse hair growth in a male-like pattern, e.g. on the face, chest or back. or acne could have a positive impact on the mental health of women with hyperandrogenism. She emphasized that PMOS still remains an under-researched area.

Trevor M. Penning

Professor in Pharmacology Department of Systems Pharmacology & Translational Therapeutics, University of Pennsylvania Perelman School of Medicine

Trevor M. Penning is an expert in steroid-transforming aldo-keto reductases, including AKR1D1. He was consulted to assess the use of AKR1D1 in our approach, and to discuss potential limitations. He confirmed the enzyme converts testosterone to 5β-DHT5β-dihydrotestosterone, the less active form of testosterone after 5β-reduction. quite well, affirming our effectorThe part of the system that carries out the intended action, here the enzyme that transforms the steroid. choice. He noted that AKR1D1’s broad substrate affinity could present an issue and that multiple point mutationsChanges to single amino acids in a protein, made by altering one letter of its gene. across the binding pocket would be needed to overcome this challenge, which could pose difficulties within our limited timeline.

Ana Nordberg

Associate Professor in Health Law Department of Law, Lund University

Ana Nordberg is an expert in health law and human rights. Her area of expertise also includes regulation of emerging biotechnologies including genome editing, synthetic biology and health data governance. She was contacted to increase understanding of EU and Swedish law, specifically focusing on consent and GDPRThe EU General Data Protection Regulation, the rules for handling personal data. regulations as well as first insights into ethical considerations when handling health-related data. Her input served as a valuable starting point for the Clinician Survey and Patient Survey (not run).

Elisabet Stener-Victorin

Professor of Reproductive Physiology Karolinska Institutet

Elisabet Stener-Victorin is an expert in PMOS, reproductive endocrinology, hyperandrogenism, and metabolic dysfunction, whose research closely aligns with our project. We contacted her to evaluate the clinical relevance of targeting androgen activity through the gut and to better understand which aspects of hyperandrogenism are most important in PMOS. Her insights led us to realize our reduction target is free testosterone, rather than SHBGSex hormone-binding globulin, a blood protein that holds sex hormones in an inactive, bound form.-bound one, along with framing AKR1D1 as a proof of concept rather than a definitive therapeutic target.

Suman Rice

Reader in Reproductive Physiology School of Health and Medical Sciences, University of London

Suman Rice is a reproductive physiologist specializing in women's reproductive health, so we contacted her to better understand the hormonal complexity of PMOS and evaluate our androgen-targeting approach. She emphasized that PMOS is highly complex and that treatment needs to differ depending on symptoms, age, and life stage. Based on her feedback, we decided to define our target patient group and treatment goal more clearly, while paying greater attention to the safety and limitations of androgen reduction.

Christina Wennerberg

Project Assistant Division of Biotechnology and Applied Microbiology, Lund University

Christina Wennerberg is a project assistant at LTH who actively implements sustainability practices in student labs. We contacted her to get her opinion on our own lab practices and her input on what a student-oriented "Sustainability in the Lab" lecture should focus on. She gave positive feedback on the lecture concept, helped us define the target audience and framing, and agreed to review the final lecture and help advertise it to students.

Johan Tejler

Work Environment Coordinator Lund University

Johan Tejler is the work environment coordinator at the Department of Chemistry at Lund University. He coordinates the work safety regarding chemicals, waste and water management at Kemicentrum (KC), where our lab was located. We contacted him because he has an overview of the regulations that need to be adhered to, as well as of ongoing projects regarding safety and sustainability in KC. We discussed with him our ideas for improving sustainability in the laboratory we were working in and came to realize that KC has already implemented many sustainable practices.

Nelida Leiva Eriksson

Associate Professor in Molecular Biotechnology Division of Applied Microbiology and Microbiology, Lund University

Nelida Leiva Eriksson is an Associate Professor and Senior Lecturer, with a field of research in biochemistry, molecular biology and synthetic biology. Considering she was a PI for iGEM teams in the past, she was contacted for insight on how to organize the technical development at project start. To minimize the risk of not finishing our project, she suggested prioritizing a better characterized 5β-reductase, such as AKR1D1. If we wanted to express both AKR1D1 and ci2350, she advised us to parallelize their expression in order to make the lab work more time-efficient. She stressed the importance of teamwork and out-of-office activities in strengthening the team bond.

Savvina Leontakianakou (not finished)

Doctoral student in Enzyme Technology, former iGEM judge Division of Biotechnology and Applied Microbiology, Lund University

Savvina Leontakianakou is a doctoral student in enzyme technology. She was a member of the 2019 iGEM Lund team that won a gold medal and has since served as an iGEM judge. We contacted her to troubleshoot our NADPHA molecule that carries electrons for enzymes. Its level can be followed by light absorbance to measure enzyme activity.-based enzyme assay, after our empty-vectorA control carrying the plasmid without our gene. control showed activity (assay development), and to ask how to structure the Design-Build-Test-Learn (DBTLDesign-Build-Test-Learn: the engineering cycle iGEM teams use.) cycle on the wiki. She advised us on handling the background activity, setting up the controls and keeping the DBTL cycles connected.

Liisa Veerus

Postdoctoral Fellow in the lab of Dr. Martin Blaser Center for Advanced Biotechnology and Medicine, Rutgers University

Liisa Veerus is a Postdoctoral Fellow researching interdependence between the microbiome and health. She was contacted via email for her perspective on the mechanistic direction of the project. She confirmed that the 5β-reduction strategy is a reasonable and experimentally tractable starting point, noting that direct androgen biotransformation provides clear, measurable outputs in vitro, and that a reductionist approach is the right way to begin.

Integration:

  • Effector choice - Liisa's feedback that the 5β-reduction strategy is a valid starting point reinforced our choice to use it for our proof-of-concept.

Juan Pablo del Río

Specialist in Child and Adolescent Psychiatry Department of Child and Adolescent Psychiatry and Mental Health, University of Chile

Dr. Juan Pablo del Río researches how prenatal and adolescent hyperandrogenism affects brain development and neuropsychiatric outcomes, including the "dual-hit hypothesisThe idea that an early exposure makes the brain vulnerable and a later second stressor then triggers disease." linking early androgen exposure to later mental health risk. He was contacted to understand how a gut-localized, androgen-lowering therapeutic like ours might intersect with the neuropsychiatric burdens seen in PMOS. His insight gave us a new perspective on whether gut testosterone reduction could plausibly extend to systemic or brain-level effects. 

Martin Hedström

Senior lecturer in Bioanalytical Chemistry Division of Biotechnology and Applied Microbiology, Lund University

Martin Hedström is a bioanalytical chemist, with main fields of work in mass spectrometry, immunoanalysis and biosensors. He was contacted for advice on how to approach detecting and quantifying steroids in our experimental work. While we initially opted to use mass spectrometry for steroid detection, Martin suggested looking into the possibility of using an enzymatic assay for leftover testosterone from our testosterone reduction assays, given the cost and complexity of mass spectrometry equipment.

Mahnaz Bahri-Khomami

Adjunct Senior Research Fellow in Women's Health Monash Center for Health Research and Implementation, Monash University

Dr. Mahnaz Bahri-Khomami was a lead researcher on the international PMOS guideline development and name-change consensus process. We contacted her to gain more insight into unmet clinical needs, research gaps, and patient priorities in PMOS. Given the time difference between Sweden and Australia, she agreed to a written interview. She answered our questions within her area of expertise which covers clinical need, patient priorities, safety, and terminology, and connected us with further experts for our biochemical and microbiome-related questions.

Nelly Garcia Gonzalez

Associate Senior Lecturer in Materials Engineering Division of Environmental and Energy System Studies, Lund University

Nelly Garcia Gonzalez is an Associate Senior Lecturer in the Division of Environmental and Energy Systems Studies at Lund University. Her work centers on bio-based materials and sustainability and she has extensively worked on making Life Cycle Assessments (LCA)A method for measuring the total environmental impact of a product from raw materials to disposal.. We reached out to her for her expertise in LCA, aiming to decide if performing an LCA for our project was possible.

iGEM Munich 2025

Winning team of Best Wiki award in the iGEM 2025 Competition Anna Tichá, Jonas Turzanski Fortner and Giuseppe Oricchio

The 2025 iGEM Munich team won Best Wiki, among other awards. To make our wiki the best representation of our project, we contacted team members to learn what they thought contributed to the win. In a call, we spoke with Anna Tichá (lead designer of the wiki), Jonas Turzanski Fortner (lead coder of the wiki) and Giuseppe Oricchio (project manager). Following their advice, we set up a system that lets everyone on our team write directly to the wiki, adjusted our design elements to improve accessibility, and added navigation and glossary components to make the wiki easier to move around in. When we asked about fancy graphics and complex animations, their advice was “less is more”, so we focused on usability and readability.

Clinicians

Lina Zabulienė

Endocrinologist with expertise in PMOS Vilnius University

Dr. Lina Zabulienė is an endocrinologist with extensive clinical and research experience in PMOS. We contacted her to discuss the target patients and safety of our gut-based therapy. Her feedback highlighted the need to avoid excessive androgen reduction and strengthened our focus on gut-specific expression, and a kill switch for bacterial containment.

Angelica Lindén Hirschberg

Professor of Obstetrics and Gynecology and Senior Consultant in Gynecological Endocrinology Karolinska Institutet

Angelica Lindén Hirschberg is a Senior Consultant and Professor, whose research focuses on disorders of reproductive function and gonadal development in women. We reached out to receive her clinical perspective on our project and its feasibility. She confirmed that targeting testosterone is a sound first step, and that the gut-localized approach is plausible, given known enterohepatic recirculationSubstances released from the liver into the gut via bile are reabsorbed and carried back to the liver, instead of leaving the body. of androgens.

Katia Palombino

Gynecologist and endocrinologist, with a focus on PMOS Private practice and public hospital work in San Severo, Foggia, Italy

Katia Palombino is a gynecologist based in southern Italy. She treats PMOS with a strong focus on lifestyle and nutrition. We contacted her to understand how PMOS is diagnosed and treated in practice. She was also willing to take part in our survey.

Industry

Lars Mattiasson

Business developer and project manager Future by Lund

Lars Mattiasson is our contact at Future by Lund, introduced via last year's iGEM Lund team. Future by Lund supported us as an infrastructure partner, giving us venue access and promotional support for our PMOS awareness workshop, supporting us on the work towards the SDGUN Sustainable Development Goals: 17 global goals adopted by the UN for 2030. 4 and 5, and publishing an article on their platform about our project progress.

Francesco Bez

Innovation Manager Medicon Village, Lund

Francesco has been our constant contact for industry connections, forwarding our outreach to contacts at GutFeelingLabs, ImmuneBiotech, Gedea, Vati of Sweden, and AstraZeneca, and introducing us to the Medicon Village ecosystem. Through him, we got in contact with both Magdalena Nour, CEO of Vati of Sweden, and Shahram Lavasani, CEO of ImmuneBiotech. He also gave us insight into what pursuing AnTigone beyond the iGEM Competition could look like, from company formation to lab space and incubatorA program that helps early-stage projects become companies with advice, workspace and funding. access.

Simon Ekström

Head of unit: Structural Proteomics SciLifeLab, Lund University

We met with Simon Ekström and Anton Sellerberg, researchers at SciLifeLab with expertise relevant to protein characterization and structural analysis. We reached out to receive their perspective on how we could characterize and improve our androgen-converting enzyme. They encouraged us to prioritize simple activity assays and protein production, while starting computational modeling in parallel to guide point mutations for improving enzyme performance.

Natalie Kazimierczak

Senior Director Business Development Recipharm Advanced Bio

We spoke with Natalie Kazimierczak and Shubharthi Nandi from Recipharm to introduce AnTigone and scope out whether Recipharm could support us on formulation and eventual scale-upMoving from small laboratory production to large-scale manufacturing.. Natalie walked us through Recipharm's advanced biotherapeutics business: process development, manufacturing, and quality control across their sites and what a potential collaboration path could look like.

Dimitra Manou

Head of Marketing Nordic Women's Health Hub

The Nordic Women's Health Hub is an NGO working to advance women's health across the Nordic region, built around four pillars: innovation, knowledge, activism, and partnerships. Dimitra Manou was our first point of contact there.

Magdalena Nour

CEO of Vati of Sweden Vati of Sweden

Magdalena Nour leads Vati of Sweden, a consultancy that helps organizations integrate the UN SDGs into their strategy and reporting. We contacted her to get insights on our SDG framing and to find practical, low-effort ways to measure and document our sustainability impact. She confirmed our five chosen SDGs were well-suited to our project, and pushed us toward a transparency-first approach, openly naming both the positive and negative impacts of our work rather than aiming for a spotless record.

Shahram Lavasani

Ph.D. in Immunology CEO of ImmuneBiotech

Dr. Shahram Lavasani was introduced to us by our contact at Medicon, Francesco Bez, who recognized that our project aligned with his company's research area. Dr. Lavasani's company, ImmuneBiotech, works with precision probiotics to manage various gastrointestinal and neurological conditions (e.g., SIBOSmall intestinal bacterial overgrowth: too many bacteria in the small intestine, which normally holds few., chronic fatigue syndrome, etc.). Dr. Lavasani advised against integrating our construct into a Lactobacillus chassis, recommending instead that we polish our results in E. coli due to time limitations and the difficulty of working with Gram-positiveBacteria with a thick cell wall that stains purple in the Gram test. They are harder to engineer than Gram-negative bacteria such as E. coli. bacteria. He also pointed us to several delayed-release capsule options for probiotic delivery that we could explore in the future.

Nicolas Arriagada

Innovation Developer LU Innovation, Lund

Nicolas is an innovation developer at LU Innovation, Lund and was our contact person throughout the project. LU Innovation guides students and researchers through the early phases of exploring and verifying an idea. We contacted them to understand what AnTigone could become beyond iGEM and what support exists for taking it further. Based on a first market analysis report, they accepted us into their incubator, where they became our main contact for the entrepreneurial side of the project and remain our most likely route if we continue after the iGEM competition.

PMOS Surveys

To assess our approach, we developed two surveys and refined them with expert feedback on their legal and clinical aspects.

The clinician survey asked 36 clinicians about current PMOS treatment, their frustrations, and their view of a hypothetical gut-targeted probiotic; 13 responded. The patient survey covered symptoms, treatment experience and openness to a non-hormonal alternative. We did not publish it, because we lacked time to secure the ethical review required for processing health-related personal data.

Clinician Survey

Clinician perspectives on PMOS treatments.

We asked 36 clinicians about current PMOS treatment, their frustrations, and their view of a hypothetical gut-targeted probiotic. 13 responded (36%). Most saw the idea as interesting but wanted more data. Their main concerns were long-term safety, colonization and missing trial data.

Patient Survey (not run)

Patient perspectives on living with PMOS. Survey was not published.

Alongside the clinician survey, we designed a second survey to hear about patients' experience directly: symptom severity and its impact on daily life, treatment experience and satisfaction, gut health symptoms, and openness to a non-hormonal, probiotic-based alternative. It was not published because we lacked time to secure the ethical review required for health-related data from this population.

References

  1. Penning, T. M. (2023). Steroid 5β-reductase (AKR1D1): Purification and characterization. Methods in Enzymology, 689, 277–301. https://doi.org/10.1016/bs.mie.2023.04.012
  2. World Health Organization. (2026, January 22). Polycystic ovary syndrome [Fact sheet]. https://www.who.int/news-room/fact-sheets/detail/polycystic-ovary-syndrome